secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001193125-24-027629
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics appoints Ivana Magovcevic-Liebisch, Ph.D., J.D., to board of directors
--------------------------------------------------------------------------------

- Appointment effective February 8, 2024; she will receive 32,500 stock options vesting over 3 years.
- Dr. Magovcevic-Liebisch is President and CEO of Vigil Neuroscience and brings 25+ years of industry experience.
- She will enter into standard indemnification agreement and receive cash compensation per non-employee director policy.
- No arrangements or transactions requiring disclosure under Item 404(a) exist with her selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312524027629/0001193125-24-027629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312524027629/d750834d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-027629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer